female pattern hair loss in postmenopausal women female pattern hair loss, androgenetic alopecia, alopecia, miniaturization, finasteride, minoxidil, topical combination
Conditions
Interventions
Topical formulation containing 0.25% finasteride and 3% minoxidil apply 1 ml of the study solution on the balding area twice daily,Topical formulation containing 0.5% finasteride and 3% minoxidil appl
Sponsors
Strategic Wisdom and Research Institute - SWURI
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Female volunteers with female pattern hair loss (FPHL) at a mild to moderate level (Ludwig grade I to II) 2.Age 18-75 years old who are postmenopausal or have undergone surgical sterilization due to oophorectomy or hysterectomy 3.Able to attend scheduled appointments and consent to the study
Exclusion criteria
Exclusion criteria: 1.History of estrogen-dependent cancers, including breast cancer, ovarian cancer, or uterine cancer. 2.Family history of breast cancer in first-degree relatives. 3.History of allergy to finasteride or minoxidil. 4.History of allergy to any of the formulation components, including ethanol, butylene glycol, or sterile water. 5.History of depression or suicidal ideation, screened using the 2Q & 9Q depression screening questionnaires. 6.History of underlying medical conditions that may contribute to hair loss, such as anemia, hypo/hyperthyroidism, systemic lupus erythematosus (SLE), malnutrition, or trichotillomania. 7.History of oral medication use that affects hair growth within 6 months before study enrollment, including: Minoxidil, finasteride, dutasteride, flutamide, spironolactone, cyproterone acetate Cimetidine, diazoxide, cyclosporin, ketoconazole, anticonvulsants, or chemotherapy drugs 8.History of topical medication use that affects hair growth within 3 months before study enrollment, such as minoxidil or finasteride. 9.History of other hair loss treatments within 3 months before study enrollment, including low-level laser/light therapy, platelet-rich plasma (PRP) therapy, or hair transplantation. 10.History of other scalp dermatologic conditions, such as psoriasis or scalp fungal infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hair density baseline and 24 weeks after treatment Quantitative videodermoscopy | — |
Secondary
| Measure | Time frame |
|---|---|
| Hair diameter baseline and 24 weeks after treatment Quantitative videodermoscopy,Hair density baseline and 24 weeks after treatment Global photography,Patient satisfaction baseline and 24 weeks after treatment 10-point visual analog scale (VAS),Adverse Events (e.g. pruritus, erythema, dry skin, dizziness or headache, breast enlargement or tenderness, decrease libido, depression) baseline and 24 weeks after treatment Patient report | — |
Countries
Thailand
Contacts
Public ContactSaranya Khunkhet
Department of Dermatology, Faculty of Medicine, Srinakharinwirot University
Outcome results
None listed